MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-07-2025
NovaBay Pharmaceuticals ROA Ratio 2011-2026 | NBY
Annual ROA Ratio NovaBay Pharmaceuticals
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -211.01 | -106.71 | -64.69 | -24.29 | -72.44 | -86.08 | -69.92 | -73.45 | -85.5 | -373.7 | -201.59 | -102.5 | -36.53 | -31.85 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -24.29 | -373.7 | -110.02 |
Quarterly ROA Ratio NovaBay Pharmaceuticals
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -18.46 | -12.64 | -25.21 | -131.64 | -145.31 | -127.72 | -100.06 | -38.12 | -38.73 | -25.66 | -22.95 | -11.06 | -29.76 | -47.86 | -51.52 | -43.16 | -64.29 | -66.73 | -82.48 | -60.93 | -63.45 | -44.82 | -37.7 | -62.14 | -78.57 | -92.49 | -87.17 | -56.37 | -80.65 | -88.5 | -88.77 | -81.32 | -105.61 | -105.62 | -105.86 | -74.79 | -178.04 | -257.0 | -335.77 | -256.41 | -312.38 | -265.11 | -207.89 | -142.31 | -166.9 | -135.51 | -122.34 | -433.32 | -432.9 | -407.9 | -393.6 | -24.32 | -23.65 | -23.4 | -9.17 | -9.13 | 0.66 | 2.66 | -12.45 |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2.66 | -433.32 | -110.92 |
ROA Ratio of other stocks in the Biotechnology industry
| Issuer | ROA Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-20.13 | - | 2.43 % | $ 254 M |  Germany |
 |
Adagene
ADAG
|
-37.44 | $ 2.62 | 28.82 % | $ 147 M |  China |
 |
GlaxoSmithKline plc
GSK
|
6.44 | $ 48.98 | 0.68 % | $ 173 B |  Britain |
 |
Acorda Therapeutics
ACOR
|
-232.99 | - | -24.86 % | $ 820 K |  USA |
 |
Aeterna Zentaris
AEZS
|
-10.45 | - | 5.93 % | $ 314 M |  Canada |
 |
Alterity Therapeutics Limited
ATHE
|
-31.06 | $ 3.51 | 7.34 % | $ 8.45 B |  Australia |
 |
AgeX Therapeutics
AGE
|
-123.72 | - | -10.17 % | $ 12.2 K | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
3.33 | - | - | $ 40.3 B | USA |
 |
Grifols, S.A.
GRFS
|
1.38 | $ 9.25 | 1.49 % | $ 6.83 B |  Spain |
 |
Biophytis SA
BPTS
|
-89.6 | - | -13.47 % | $ 169 M |  France |
 |
Aeglea BioTherapeutics
AGLE
|
-34.19 | - | - | $ 1.01 B | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
10.11 | $ 25.92 | -0.86 % | $ 1.26 B | USA |
 |
Midatech Pharma plc
MTP
|
-42.28 | - | -18.52 % | $ 27.3 M | Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-53.39 | - | -1.52 % | $ 24.7 M | USA |
 |
Akero Therapeutics
AKRO
|
-30.52 | - | - | $ 3.67 B | USA |
 |
Galapagos NV
GLPG
|
-1.99 | $ 34.61 | 0.61 % | $ 2.69 B |  Belgium |
 |
Ultragenyx Pharmaceutical
RARE
|
-37.86 | $ 24.45 | 4.49 % | $ 2.21 B | USA |
 |
Aptose Biosciences
APTO
|
-251.11 | - | -45.71 % | $ 1.2 M | Canada |
 |
Aravive
ARAV
|
-122.8 | - | -13.39 % | $ 1.45 M | USA |
 |
Athira Pharma
ATHA
|
-164.92 | - | - | $ 269 M | USA |
 |
Akouos
AKUS
|
-31.09 | - | 0.23 % | $ 488 M | USA |
 |
AVROBIO
AVRO
|
12.03 | - | 1083.1 % | $ 745 M | USA |
 |
BioLineRx Ltd.
BLRX
|
-33.24 | $ 3.1 | 4.49 % | $ 908 M |  Israel |
 |
Applied Molecular Transport
AMTI
|
-117.57 | - | - | $ 10.1 M | USA |
 |
BioNTech SE
BNTX
|
65.02 | $ 116.27 | -1.86 % | $ 27.2 B | Germany |
 |
Институт стволовых клеток человека
ISKJ
|
4.82 | - | - | - |  Russia |
 |
Ascendis Pharma A/S
ASND
|
-35.36 | $ 235.41 | 2.95 % | $ 5 B |  Danmark |
 |
BioXcel Therapeutics
BTAI
|
-155.46 | $ 1.84 | 1.66 % | $ 4.66 M | USA |
 |
Burford Capital Limited
BUR
|
5.51 | $ 9.74 | -1.37 % | $ 1.55 B | Britain |
 |
ARCA biopharma
ABIO
|
-21.14 | - | 1052.0 % | $ 415 M | USA |
 |
Aytu BioScience
AYTU
|
-10.92 | $ 2.66 | -1.85 % | $ 16.7 M | USA |
 |
Acasti Pharma
ACST
|
-13.29 | - | 4.01 % | $ 150 M | Canada |
 |
Arrowhead Pharmaceuticals
ARWR
|
-0.12 | $ 67.49 | -3.02 % | $ 9.03 B | USA |
 |
Brickell Biotech
BBI
|
-49.15 | - | -5.38 % | $ 6.06 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-86.4 | $ 4.51 | 8.41 % | $ 9.81 B | Israel |
 |
BeiGene, Ltd.
BGNE
|
-10.89 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Ayala Pharmaceuticals
AYLA
|
-489.29 | - | - | $ 7.46 M | Israel |
 |
Adaptimmune Therapeutics plc
ADAP
|
-40.29 | - | -15.15 % | $ 60.3 M | Britain |
 |
AIkido Pharma
AIKI
|
-31.2 | - | 1.93 % | $ 17.4 M | USA |
 |
Albireo Pharma
ALBO
|
-11.27 | - | -0.23 % | $ 916 M | USA |
 |
CureVac N.V.
CVAC
|
-35.55 | - | - | $ 867 M | Germany |
 |
Acer Therapeutics
ACER
|
-225.71 | - | 2.71 % | $ 14 M | USA |
 |
Bellicum Pharmaceuticals
BLCM
|
-104.83 | - | -9.72 % | $ 5.89 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-20.15 | - | - | $ 2.17 B | USA |
 |
AlloVir
ALVR
|
-49.57 | - | 4.14 % | $ 49.1 M | USA |
 |
Coherus BioSciences
CHRS
|
-37.78 | $ 2.04 | 28.3 % | $ 192 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-150.49 | - | -11.43 % | $ 502 K | USA |
 |
Biogen
BIIB
|
5.82 | $ 171.89 | -1.1 % | $ 25 B | USA |
 |
Bio-Path Holdings
BPTH
|
-499.32 | - | - | $ 100 K | USA |
 |
BioVie
BIVI
|
-81.36 | $ 1.2 | -3.7 % | $ 1.77 M | USA |